Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)
ID: 357019Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357019

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-325.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)" aimed at fostering collaborative research partnerships between academic and industrial investigators to accelerate the development of innovative bioengineering tools and technologies. The program seeks to establish multidisciplinary teams that apply a quantitative bioengineering approach to address significant biomedical challenges, with a focus on creating robust solutions that can enhance life science understanding and medical practices within a 5-10 year timeframe. Eligible applicants include a diverse range of organizations such as higher education institutions, nonprofits, and for-profit entities, particularly those emphasizing diversity in research. Interested parties should note that the application deadline is September 7, 2027, and for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information page at https://grants.nih.gov/grants/guide/pa-files/PAR-24-325.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-325-Full-Announcement.html
    PAR-24-325.html
    The Department of Health and Human Services announces a funding opportunity titled "Bioengineering Partnerships with Industry," aimed at accelerating the development and adoption of innovative bioengineering tools and technologies that address critical biomedical challenges. This program encourages collaborative partnerships between academic researchers and industry stakeholders to create multidisciplinary teams focused on engineering solutions with a clear timeline and measurable goals within a 5-10 year timeframe. Key eligible applicants include higher education institutions, nonprofits, and for-profit organizations, particularly those that emphasize diversity and inclusion in research. The program requires a Leadership Plan detailing the roles and contributions of each team member, especially the industrial partner. Applications will undergo rigorous peer review based on factors such as significance, innovation, approach, and the expertise of investigators. The anticipated funding supports cooperative agreements, with no specific budget limits, subject to project needs, and follows strict compliance with NIH policies. The initiative recognizes the essential role of industry in transforming technologies into robust solutions that meet the needs of the medical community and ultimately enhance patient care.
    Similar Opportunities
    Notice of Intent to Publish a Funding Opportunity Announcement for Biomedical-engineering Partnership with Industry (U01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity for the Biomedical-engineering Partnership with Industry (U01 Clinical Trial Not Allowed) aimed at fostering collaborations between academic and industrial organizations to develop innovative biomedical solutions. This initiative encourages the establishment of robust engineering solutions to address significant biomedical challenges, requiring applicants to form strategic alliances and outline a detailed plan with specific milestones to achieve results within 5-10 years. The anticipated funding opportunity announcement is expected to be published in February 2022, with applications due by May 2022, and the estimated award date is set for April 1, 2023. For further inquiries, interested parties can contact Dr. I. George Zubal at 301-827-5168 or via email at igeorge.zubal@nih.gov.
    Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Bioengineering Research Grants (BRG) to encourage multidisciplinary collaborations that address significant biomedical challenges through innovative technologies. This funding opportunity aims to integrate life and physical sciences to accelerate the adoption of promising tools and methods in clinical or translational science, with a focus on projects that may involve clinical trials assessing functionality or performance in real-world settings. Eligible applicants include a wide range of organizations such as higher education institutions, non-profits, and foreign entities, with no cost-sharing requirement, and applications are due by September 7, 2025. For more information, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-22-243.html.
    Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Bioengineering Research Grants (BRG), aimed at fostering multidisciplinary collaborations to address significant biomedical challenges. This funding opportunity encourages innovative research that integrates life and physical sciences to develop tools, methods, and technologies that can enhance healthcare delivery and medical practices. Eligible applicants include a diverse range of institutions, such as historically black colleges, tribal colleges, and community-based organizations, with projects allowed to span up to five years under the R01 grant mechanism. Interested parties should submit their applications electronically by September 7, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering funding through the Exploratory/Developmental Bioengineering Research Grants (EBRG) program, aimed at enhancing biomedical research and clinical care. This initiative encourages innovative applications that focus on developing new capabilities to address challenges in biomedical, preclinical, or clinical settings, with an emphasis on feasibility testing and novel methodologies. The program is particularly significant for advancing cancer research through innovative bioengineering approaches, welcoming proposals from a diverse range of eligible applicants, including universities, nonprofits, and small businesses, especially those representing underrepresented groups. The maximum budget for applicants is $275,000 over two years, with applications due by January 7, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-321.html.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)." This initiative aims to foster interdisciplinary research teams that can translate scientific discoveries into practical tools and methods for diagnosing and treating diseases, addressing both clinical and non-clinical challenges. The program is particularly significant for enhancing cancer research and improving patient care outcomes, with a maximum funding amount of $499,000 per year available for projects lasting up to five years. Applications will be accepted starting January 5, 2025, with a closing date of January 8, 2028. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-25-337.html.
    Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)." This initiative aims to foster collaborations between academic and industrial entities to develop innovative solutions for critical health challenges, particularly in the fields of cancer and eye health. The program encourages interdisciplinary research teams to enhance and validate technologies that improve diagnostic methods and treatment capabilities, ultimately supporting better health outcomes for diverse populations. The funding amount is capped at $499,000 annually, with a maximum project duration of five years. Initial submissions are due by January 5, 2025, and interested applicants can find more information at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed), aimed at advancing innovative bioengineering solutions to address cancer and other biomedical challenges. This funding opportunity encourages projects that demonstrate the feasibility and potential utility of novel capabilities to enhance biomedical research, clinical care delivery, and accessibility, while specifically discouraging clinical trial proposals. Eligible applicants include a diverse range of institutions such as higher education entities, nonprofits, for-profit organizations, and foreign entities, with a funding cap of $275,000 available over a two-year period. Interested applicants can find more information and submission guidelines on the NIH website, with applications due by January 7, 2028. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Enhancing Biomedical Engineering, Imaging, and Technology Acceleration (BEITA) at Historically Black Colleges and Universities (HBCUs) (UG3/UH3 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Enhancing Biomedical Engineering, Imaging, and Technology Acceleration (BEITA) at Historically Black Colleges and Universities (HBCUs)." This initiative aims to enhance research capacity, technology innovation, and educational opportunities in biomedical engineering and related fields at HBCUs through a two-phase funding approach, with Phase I (UG3) offering up to $300,000 annually for planning and Phase II (UH3) allowing for up to $1,000,000 per year for full-scale program implementation. The program emphasizes the importance of diversity in the scientific workforce and seeks to leverage HBCUs' talent to address health disparities in the U.S. Interested applicants must submit their proposals by September 30, 2025, and can find additional information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "National Centers for Biomedical Imaging and Bioengineering (NCBIB)" aimed at supporting the development and dissemination of new biomedical technologies. This initiative encourages applications from a diverse range of eligible entities, including higher education institutions and nonprofit organizations, to conduct technology research and development projects, collaborative projects, and service projects that address biomedical challenges. The program is designed to foster innovative research and enhance clinical applications, with funding typically ranging from $600,000 to $750,000 per project, and awards may last up to five years, with a total funding cap of fifteen years for any Center. Interested applicants should note that the application process opens on September 25, 2023, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov. For more details, please refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-23-235.html.
    Building Biomedical Engineering Education, Research, and Innovation at Historically Black Colleges and Universities (HBCU eBETA) (UG3/UH3 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Building Biomedical Engineering Education, Research, and Innovation at Historically Black Colleges and Universities (HBCU eBETA)," aimed at enhancing research capacity and technology innovation in biomedical engineering at HBCUs. This initiative seeks to bolster education and career development in biomedical engineering, with a phased funding approach allowing for up to $300,000 in direct costs for planning (UG3 Phase) and potentially up to $1,000,000 for full-scale program implementation (UH3 Phase). The program emphasizes the importance of diversity in the scientific workforce and aims to address health disparities through improved training and partnerships. Interested applicants must submit their proposals by September 30, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/rfa-files/RFA-EB-25-002.html.